Effects of Rock Steady Boxing on Activities of Daily Living and Motor Symptoms of Parkinson’s Disease
Objective: To determine the impact of the Rock Steady Boxing (RSB) program on Parkinson’s disease (PD). To assess the feasibility of data collection for activities…VY-AADC01 gene therapy in Parkinson’s disease: Interim results of the on-going Phase 1b PD-1101 trial
Objective: Evaluate the safety of VY-AADC01, an AAV2 gene therapy vector with human aromatic L-amino acid decarboxylase (AADC) administered bilaterally to the putamen using intraoperative…NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders
Objective: The objective of NS-PARK/FCRIN network (http://www.parkinson.network/) is to facilitate and stimulate clinical academic and industrial research in France in the field of Parkinson's disease…Improving Racial and Ethnic Diversity in Parkinson`s Disease Clinical Trials
Objective: To identify and overcome challenges to recruiting minorities in Parkinson's Disease experimental therapeutic trials. Background: Inadequate representation of ethnic and minority population poses substantial…Sample size estimation for clinical trials in de novo Parkinson’s disease (PD): Results from the Parkinson’s Progression Markers Initiative (PPMI) Study
Objective: To use clinical and biological data from PPMI to estimate sample size for disease modification studies in de novo PD Background: One barrier to…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.
Objective: Assesing the neurorestorative effect of GDNF. Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Intracerebroventricular administration of dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: In this study, we aim to demonstrate that continuous i.c.v. infusion of dopamine close to the striatum is a feasible and highly efficient treatment…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.